Expand SNGX Menu
SNGX MENU

SNGX Latest Press Releases

-- August 7, 2026 --

Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results PRNewswire 7:31 AM

-- June 8, 2026 --

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine PRNewswire 7:30 AM

-- May 26, 2026 --

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo PRNewswire 7:30 AM

-- May 8, 2026 --

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results PRNewswire 7:30 AM

-- April 28, 2026 --

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte in Treatment of Cutaneous T-Cell Lymphoma PRNewswire 7:30 AM

-- April 2, 2026 --

Positive Clinical Results from HyBryte Comparative Study Evaluating HyBryte Against Valchlor in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy PRNewswire 7:30 AM

-- March 31, 2026 --

Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results PRNewswire 7:30 AM

-- March 26, 2026 --

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behet's Disease PRNewswire 7:30 AM

-- March 23, 2026 --

HyBryte Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026 PRNewswire 7:30 AM

-- March 19, 2026 --

IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc. Globe Newswire 8:00 AM
Soligenix Announces HyBryte Clinical Summary Published in "Expert Opinion on Investigational Drugs" PRNewswire 7:30 AM

-- March 10, 2026 --

Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency PRNewswire 7:30 AM
Market Data Delayed 15 Minutes